1

South Australia Trans-Tasman Mutual Recognition (South Australia) Regulations 2015 under the Trans-Tasman Mutual Recognition (South Australia) Act 1999

Contents 1 Short title 3 Interpretation 4 Temporary exemptions—synthetic drugs 5 Temporary exemption—MDMB-CHMICA 6 Temporary exemption—certain controlled drugs Schedule 1—Temporary exemptions—synthetic drugs Legislative history

1—Short title These regulations may be cited as the Trans-Tasman Mutual Recognition (South Australia) Regulations 2015. 3—Interpretation In these regulations— Act means the Trans-Tasman Mutual Recognition (South Australia) Act 1999. 4—Temporary exemptions—synthetic drugs (1) For the purposes of section 5 of the Act and section 46 of the Commonwealth Act— (a) the substances specified in Schedule 1 are declared to be exempt from the operation of the Commonwealth Act; and (b) the provisions of the Controlled Substances (Controlled Drugs, Precursors and Plants) Regulations 2014 inserted by the Controlled Substances (Controlled Drugs, Precursors and Plants) Variation Regulations 2015 are declared to be exempt from the operation of the Commonwealth Act. (2) The exemptions from the Commonwealth Act under subregulation (1) have effect for a period of 12 months following the commencement of this regulation. 5—Temporary exemption—MDMB-CHMICA (1) For the purposes of section 5 of the Act and section 46 of the Commonwealth Act— (a) the substance methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate (MDMB-CHMICA) and any preparation containing that substance are declared to be exempt from the operation of the Commonwealth Act; and (b) the provisions of the Controlled Substances (Controlled Drugs, Precursors and Plants) Regulations 2014 referring to the substance specified in paragraph (a) (inserted by regulation 4(4) of the Controlled Substances (Controlled Drugs, Precursors and Plants) Variation Regulations 2015) are declared to be exempt from the operation of the Commonwealth Act. (2) The exemptions from the Commonwealth Act under subregulation (1) have effect for a period of 12 months following the commencement of this regulation. 6—Temporary exemption—certain controlled drugs (1) For the purposes of section 5 of the Act and section 46 of the Commonwealth Act— (a) the substances to which this regulation applies and any preparation containing 1 or more of those substances are declared to be exempt from the operation of the Commonwealth Act; and (b) the provisions of the Controlled Substances (Controlled Drugs, Precursors and Plants) Regulations 2014 referring to a substance to which this regulation applies (inserted by the Controlled Substances (Controlled Drugs, Precursors and Plants) (Miscellaneous) Variation Regulations 2017) are declared to be exempt from the operation of the Commonwealth Act. (2) The exemptions from the Commonwealth Act under subregulation (1) have effect for a period of 12 months following the commencement of this regulation. (3) This regulation applies to the following substances: (a) acetyl fentanyl; (b) butyryl fentanyl; (c) clonazolam; (d) deschloroetizolam; (e) N,N-Dialkylaminocyclohexyl alkyl benzamides (not otherwise listed in Schedule 1 of the Controlled Substances (Controlled Drugs, Precursors and Plants) Regulations 2014); (f) N,N-Dialkylaminocyclohexylmethyl alkyl benzamides (not otherwise listed in Schedule 1 of the Controlled Substances (Controlled Drugs, Precursors and Plants) Regulations 2014); (g) 3,4-dichloro-N-[2-(dimethylamino)cyclohexyl] -N-methylbenzamide (U-47700); (h) diclazepam; (i) fentanyls (not otherwise listed in Schedule 1 of the Controlled Substances (Controlled Drugs, Precursors and Plants) Regulations 2014); (j) flubromazepam; (k) flubromazolam; (l) furanyl fentanyl; (m) meclonazepam; (n) nifoxipam; (o) ocfentanil; (p) para-fluorobutyryl-fentanyl; (q) pyrazolam. Schedule 1—Temporary exemptions—synthetic drugs 1-pentyl-3-(Adamant-1-oyl)indole (AB-001) N-(Adamant-1-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide (STS-135) 3-(1-Adamantoyl)-indoles N-(1-Adamantyl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide (5F-AKB48) N-(1-Adamantyl)-indazole-3-carboxamides N-allyl-N-[2-(5-Methoxy-1H-indol-3-yl)ethyl]prop-2-en-1-amine(N,N-diallyl-5- Methoxytryptamine or 5-MeO-DALT) N-[1-Aminocarbonyl)-2-methylpropyl]-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (AB-CHMINACA) N-[1-(Aminocarbonyl)-2-methylpropyl]-1-pentyl-1H-indazole-3-carboxamide (AB-PINACA) N-[1-(Aminocarbonyl)-2-methylpropyl]-1-[(4-fluorophenyl)methyl]-1H-indazole-3- carboxamide (AB-FUBINACA) 1-(1,3-Benzodioxol-5-yl)-2-(ethylamino)propan-1-one (Ethylone) 1-(1,3-Benzodioxol-5-yl)-2-(methylamino)butan-1-one (Butylone) 1-(1,3-Benzodioxol-5-yl)-2-(methylamino)pentan-1-one (Pentylone) 3,4 dichloro-N-[1-(dimethylamino)cyclohexylmethyl]benzamide (AH-7921) (3-Diethylamino-2,2-dimethylpropyl)-4-aminobenzoate (Dimethocaine) 6,7-dihydro-5H-cyclopenta[f][1,3]benzodioxol-6-amine (5,6- Methylenedioxy-2-aminoindane or MDAI) 2-(2,5-Dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25H-NBOMe) 2-(2,5-Dimethoxyphenyl)ethanamine (2C-H) 5-(1,1-dimethyloctyl)-2-[3-hydroxycyclohexyl]-phenol (cannabicyclohexanol) 5-(1,1-dimethylheptyl)-2-[3-hydroxycyclohexyl]-phenol (CP-47,497) 2-ethylamino-1-(4-methylphenyl)propan-1-one (4-methylethcathinone or 4-MEC) N-(1-Fenchyl)-indole-3-carboxamides 2-(4-Fluoro-2,5-dimethoxyphenyl)-1-aminoethane (2C-F) 2-(4-Fluoro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25F-NBOMe) Indazole-3-carboxamides (Indol-3-yl)-(2,2,3,3-tetra-alkylcyclopropyl)methanones Indole-3-carboxylic acid, quinolinyl esters 7-Methoxy-1-(2-morpholinoethyl)-N-1,3,3-trimethylbicyclo[2.2.1]heptan-2-yl)-1H- indole-3-carboxamide (N-Fenchyl-1-(2-morpholinoethyl)-7-methoxyindole-3- carboxamide or UR-12) 1-(4-methylphenyl)-2-(1-pyrrolidinyl)-1-propanone (4'-Methyl-α-pyrrolidinopropiophenone or 4-MePPP or MαPPP) Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate (NM2201) 1-phenyl-2-(1-pyrrolidinyl)-1-pentanone (alpha-PVP or alpha-pyrrolidinovalerophenone) 1-pentyl-N-tricyclo[3.3.1.13,7]dec-1-yl-1H-indole-3-carboxamide (N-(1-Adamantyl)-1- pentyl-1H-indole-3-carboxamide or SDB-001 or APICA) Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate (5F-PB-22) Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate (PB-22) Legislative history Notes • Please note—References in the legislation to other legislation or instruments or to titles of bodies or offices are not automatically updated as part of the program for the revision and publication of legislation and therefore may be obsolete. • Earlier versions of these regulations (historical versions) are listed at the end of the legislative history. • For further information relating to the Act and subordinate legislation made under the Act see the Index of South Australian Statutes or www.legislation.sa.gov.au. Legislation revoked by principal regulations The Trans-Tasman Mutual Recognition (South Australia) Regulations 2015 revoked the following: Trans-Tasman Mutual Recognition (South Australia) Regulations 2013 Principal regulations and variations New entries appear in bold. Year No Reference Commencement 2015 188 Gazette 23.7.2015 p3548 23.7.2015: r 2 2015 244 Gazette 3.12.2015 p5163 3.12.2015: r 2 2017 305 Gazette 7.11.2017 p4548 12.11.2017: r 2 Provisions varied New entries appear in bold. Entries that relate to provisions that have been deleted appear in italics. Provision How varied Commencement r 2 omitted under Legislation Revision and Publication Regulations 2002 3.12.2015 r 5 inserted by 244/2015 r 4 3.12.2015 r 6 inserted by 305/2017 r 4 12.11.2017 Sch 2 omitted under Legislation Revision and Publication Regulations 2002 3.12.2015 Historical versions 3.12.2015